Werbung
Werbung

CMPX

CMPX logo

Compass Therapeutics, Inc. Common Stock

5.34
USD
Gesponsert
+0.17
+3.38%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

5.40

+0.06
+1.03%

CMPX Ergebnisberichte

Positives Überraschungsverhältnis

CMPX übertreffen die 9 der letzten 17Schätzungen.

53%

Nächster Bericht

Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.10
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+25.00%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
-9.09%

Compass Therapeutics, Inc. Common Stock earnings per share and revenue

On 05. Nov. 2025, CMPX reported earnings of -0.08 USD per share (EPS) for Q3 25, beating the estimate of -0.14 USD, resulting in a 42.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.79% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an increase of 25.00% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Compass Therapeutics, Inc. Common Stock reported EPS of -$0.08, beating estimates by 42.98%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.79%, changed from $3.79 before the earnings release to $3.82 the day after.
The next earning report is scheduled for 25. Feb. 2026.
Based on 16 analysts, Compass Therapeutics, Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung